Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000655359 | SCV000777289 | uncertain significance | Cerebral creatine deficiency syndrome | 2022-08-23 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with serine, which is neutral and polar, at codon 170 of the GAMT protein (p.Asn170Ser). This variant is present in population databases (rs202199674, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with GAMT-related conditions. ClinVar contains an entry for this variant (Variation ID: 544253). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV001272270 | SCV002787588 | uncertain significance | Deficiency of guanidinoacetate methyltransferase | 2022-02-26 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001272270 | SCV001454100 | uncertain significance | Deficiency of guanidinoacetate methyltransferase | 2020-09-16 | no assertion criteria provided | clinical testing |